Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 154 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Takeda projects

154 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 154 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 4 of 4
  1. pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    4 trials
  2. pioglitazone

    Takeda

    Type 2 Diabetes

    approved small molecule completed

    1 trial
  3. placebo

    Takeda

    Constipation

    approved small molecule completed

    1 trial
  4. prucalopride

    Takeda

    Chronic Constipation

    approved small molecule completed

    1 trial
  5. ramelteon

    Takeda

    Migraine Headache

    approved small molecule terminated

    1 trial
  6. rhPTH (1-84)

    Takeda

    Hypoparathyroidism

    approved mab completed

    3 trials
  7. rhPTH(1-84)

    Takeda

    Chronic Hypoparathyroidism

    approved small molecule terminated

    2 trials
  8. rt-PA

    Takeda

    Lacunar Stroke

    approved small molecule active

    1 trial
  9. theophylline

    Takeda

    Healthy

    approved small molecule completed

    1 trial
  10. vortioxetine

    Takeda

    Depression

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

154 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.